Cargando…
Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study
BACKGROUND: Inter-individual courses of multiple sclerosis (MS) are extremely variable. The objective of this study was to investigate whether κ-free light chain (κ-FLC) index and serum neurofilament light (sNfL) have an additive predictive value for MS disease activity. METHODS: Patients with early...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148088/ https://www.ncbi.nlm.nih.gov/pubmed/37086651 http://dx.doi.org/10.1016/j.ebiom.2023.104573 |
_version_ | 1785034923711660032 |
---|---|
author | Hegen, Harald Berek, Klaus Bsteh, Gabriel Auer, Michael Altmann, Patrick Di Pauli, Franziska Grams, Astrid Milosavljevic, Dejan Ponleitner, Markus Poskaite, Paulina Schnabl, Christine Wurth, Sebastian Zinganell, Anne Berger, Thomas Walde, Janette Deisenhammer, Florian |
author_facet | Hegen, Harald Berek, Klaus Bsteh, Gabriel Auer, Michael Altmann, Patrick Di Pauli, Franziska Grams, Astrid Milosavljevic, Dejan Ponleitner, Markus Poskaite, Paulina Schnabl, Christine Wurth, Sebastian Zinganell, Anne Berger, Thomas Walde, Janette Deisenhammer, Florian |
author_sort | Hegen, Harald |
collection | PubMed |
description | BACKGROUND: Inter-individual courses of multiple sclerosis (MS) are extremely variable. The objective of this study was to investigate whether κ-free light chain (κ-FLC) index and serum neurofilament light (sNfL) have an additive predictive value for MS disease activity. METHODS: Patients with early MS who had cerebrospinal fluid (CSF) and serum sampling at disease onset were followed for four years. At baseline, age, sex, disease duration, number of T2-hyperintense (T2L), and contrast-enhancing T1 lesions (CEL) on MRI were determined. During follow-up, the occurrence of a second clinical attack and start of disease-modifying treatment (DMT) were registered. κ-FLC was measured by nephelometry, and κ-FLC index calculated as [CSF κ-FLC/serum κ-FLC]/albumin quotient. sNfL was determined by single-molecule array, and age- and body-mass-index adjusted Z scores were calculated. FINDINGS: A total of 86 patients at a mean age of 33 ± 10 years and with a female predominance of 67% were included; 36 (42%) patients experienced a second clinical attack during follow-up. Cox regression analysis adjusted for age, sex, T2L, CEL, disease and follow-up duration, and DMT use during follow-up revealed that both κ-FLC index as well as sNfL Z score independently predict time to second clinical attack. The chance for freedom of relapse within 12 months was 2% in patients with high levels of κ-FLC index (>100) and high sNfL Z score (>3), 30% in patients with high κ-FLC index (>100) and lower sNfL Z score (≤3), 70% in patients with lower κ-FLC index (≤100) but high sNfL Z score (>3), and 90% in patients with lower levels of κ-FLC index (≤100) and sNfL Z score (≤3). INTERPRETATION: κ-FLC index and sNfL Z score have an additive predictive value for early MS disease activity that is independent of known predictors. FUNDING: This study was funded by a grant of the charitable foundation of the Austrian Multiple Sclerosis Society. |
format | Online Article Text |
id | pubmed-10148088 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-101480882023-04-30 Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study Hegen, Harald Berek, Klaus Bsteh, Gabriel Auer, Michael Altmann, Patrick Di Pauli, Franziska Grams, Astrid Milosavljevic, Dejan Ponleitner, Markus Poskaite, Paulina Schnabl, Christine Wurth, Sebastian Zinganell, Anne Berger, Thomas Walde, Janette Deisenhammer, Florian eBioMedicine Articles BACKGROUND: Inter-individual courses of multiple sclerosis (MS) are extremely variable. The objective of this study was to investigate whether κ-free light chain (κ-FLC) index and serum neurofilament light (sNfL) have an additive predictive value for MS disease activity. METHODS: Patients with early MS who had cerebrospinal fluid (CSF) and serum sampling at disease onset were followed for four years. At baseline, age, sex, disease duration, number of T2-hyperintense (T2L), and contrast-enhancing T1 lesions (CEL) on MRI were determined. During follow-up, the occurrence of a second clinical attack and start of disease-modifying treatment (DMT) were registered. κ-FLC was measured by nephelometry, and κ-FLC index calculated as [CSF κ-FLC/serum κ-FLC]/albumin quotient. sNfL was determined by single-molecule array, and age- and body-mass-index adjusted Z scores were calculated. FINDINGS: A total of 86 patients at a mean age of 33 ± 10 years and with a female predominance of 67% were included; 36 (42%) patients experienced a second clinical attack during follow-up. Cox regression analysis adjusted for age, sex, T2L, CEL, disease and follow-up duration, and DMT use during follow-up revealed that both κ-FLC index as well as sNfL Z score independently predict time to second clinical attack. The chance for freedom of relapse within 12 months was 2% in patients with high levels of κ-FLC index (>100) and high sNfL Z score (>3), 30% in patients with high κ-FLC index (>100) and lower sNfL Z score (≤3), 70% in patients with lower κ-FLC index (≤100) but high sNfL Z score (>3), and 90% in patients with lower levels of κ-FLC index (≤100) and sNfL Z score (≤3). INTERPRETATION: κ-FLC index and sNfL Z score have an additive predictive value for early MS disease activity that is independent of known predictors. FUNDING: This study was funded by a grant of the charitable foundation of the Austrian Multiple Sclerosis Society. Elsevier 2023-04-20 /pmc/articles/PMC10148088/ /pubmed/37086651 http://dx.doi.org/10.1016/j.ebiom.2023.104573 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Articles Hegen, Harald Berek, Klaus Bsteh, Gabriel Auer, Michael Altmann, Patrick Di Pauli, Franziska Grams, Astrid Milosavljevic, Dejan Ponleitner, Markus Poskaite, Paulina Schnabl, Christine Wurth, Sebastian Zinganell, Anne Berger, Thomas Walde, Janette Deisenhammer, Florian Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study |
title | Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study |
title_full | Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study |
title_fullStr | Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study |
title_full_unstemmed | Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study |
title_short | Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study |
title_sort | kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148088/ https://www.ncbi.nlm.nih.gov/pubmed/37086651 http://dx.doi.org/10.1016/j.ebiom.2023.104573 |
work_keys_str_mv | AT hegenharald kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT berekklaus kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT bstehgabriel kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT auermichael kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT altmannpatrick kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT dipaulifranziska kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT gramsastrid kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT milosavljevicdejan kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT ponleitnermarkus kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT poskaitepaulina kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT schnablchristine kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT wurthsebastian kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT zinganellanne kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT bergerthomas kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT waldejanette kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy AT deisenhammerflorian kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy |